Dr.Reddy's Laboratories (RDY) Given Daily Coverage Optimism Rating of -0.01

Headlines about Dr.Reddy's Laboratories (NYSE:RDY) have trended somewhat negative on Sunday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dr.Reddy's Laboratories earned a daily sentiment score of -0.01 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.9560189710852 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

RDY has been the topic of a number of research reports. Zacks Investment Research raised shares of Dr.Reddy's Laboratories from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Jefferies Group cut their target price on shares of Dr.Reddy's Laboratories from $31.62 to $30.51 and set an “underperform” rating on the stock in a research note on Wednesday, November 1st. Finally, ValuEngine lowered shares of Dr.Reddy's Laboratories from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $30.51.

Shares of Dr.Reddy's Laboratories (NYSE:RDY) traded up $0.04 during midday trading on Friday, reaching $34.74. 148,748 shares of the company were exchanged, compared to its average volume of 410,887. Dr.Reddy's Laboratories has a one year low of $29.83 and a one year high of $44.23. The stock has a market cap of $5,760.90, a PE ratio of 37.36 and a beta of 0.23. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.13 and a current ratio of 1.50.

ILLEGAL ACTIVITY NOTICE: “Dr.Reddy's Laboratories (RDY) Given Daily Coverage Optimism Rating of -0.01” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2018/02/19/dr-reddys-laboratories-rdy-given-daily-coverage-optimism-rating-of-0-01.html.

About Dr.Reddy's Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Insider Buying and Selling by Quarter for Dr.Reddy's Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply